Ceramides Mixture

Cat. No.: HY-113679 Purity: 99.8%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Ceramides Mixture is an endogenous ceramide and consists of hydroxy and non-hydroxy fatty acid-containing ceramides. Ceramides Mixture is a main lipid component of the permeability barrier in epidermis. Ceramides Mixture is involved in the regulation of growth inhibition, cell cycle arrest, and modulation of telomerase activity.

For research use only. We do not sell to patients.

CAS No. : 100403-19-8

Size	Price	Stock
5 mg		Ask For Quote & Lead Time
10 mg		Ask For Quote & Lead Time

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

2 Publications Citing Use of MCE Ceramides Mixture

Cell Proliferation/Viability Assay

2D/3D Cell Culture and Differentiation

Apoptosis Analysis

ELISA

: Ceramides Mixture purchased from MedChemExpress. Usage Cited in: ACS Cent Sci. 2025 Jul 29;11(9):1682-1699.; Representative immunofluorescence images of OLFM4 (green) in intestinal organoids under Ceramides Mixture (Ceramide) (10 μg/mL; 48 h) and ceramide+AS-IV (5 μM; 48 h) treatments.

: Ceramides Mixture purchased from MedChemExpress. Usage Cited in: ACS Cent Sci. 2025 Jul 29;11(9):1682-1699.; Representative images of intestinal organoids treated with Ceramides Mixture (Ceramide) (10 μg/mL; 48 h) or ceramide with AS-IV (ceramide+AS-IV (5 μM; 48 h)).

: Ceramides Mixture purchased from MedChemExpress. Usage Cited in: EMBO Mol Med. 2023 Apr 11;15(4):e17450. [Abstract]; The relative cell viability of KGN cells with Ceramides Mixture (Cer, 30-60 μM; 48 h) treatment. N = 6.

: Ceramides Mixture purchased from MedChemExpress. Usage Cited in: EMBO Mol Med. 2023 Apr 11;15(4):e17450. [Abstract]; The percentage of Annexin V positive cells of KGN cells with Ceramides Mixture (Cer, 40 μM; 48 h) treatment. N = 3

: Ceramides Mixture purchased from MedChemExpress. Usage Cited in: EMBO Mol Med. 2023 Apr 11;15(4):e17450. [Abstract]; Decreases of E2 secretions from KGN cells treated with Ceramides Mixture (Cer, 30-60 μM; 48 h). N = 3.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

Endogenous Ceramides (generated in response to bacterial sphingomyelinase overexpression or daunorubicin treatment) inhibits mRNA synthesis of telomerase reverse transcriptase and telomerase activity via inactivation of c-Myc transcription factor in the A549 human lung adenocarcinoma cell line^[1].
The sustained generation of long chain endogenous ceramide requires the biochemical recycling of the sphingosine backbone of C6-ceramide, which involves deacylation and reacylation of ceramide for the generation of endogenous long chain ceramide (mainly C16:0- and C24:1-Ceramides), most likely by CoA-dependent ceramide synthase, which is inhibited by fumonisin B1. In A549 cells the generation of long chain endogenous ceramide mediates the effects of exogenous C6-ceramide on growth inhibition, cell cycle arrest, and the modulation of telomerase activity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

CAS No.

100403-19-8

Appearance

Solid

Color

White to light yellow

SMILES

[Ceramides Mixture]

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 1 mg/mL (ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 0.1 mg/mL; Clear solution

This protocol yields a clear solution of ≥ 0.1 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (1.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 0.1 mg/mL; Clear solution

This protocol yields a clear solution of ≥ 0.1 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (1.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: 0.1 mg/mL; Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 0.1 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (1.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.8%

Select Batch:

Data Sheet (269 KB) SDS (392 KB)

COA (242 KB)

Handling Instructions (2659 KB)

References

[1]. Ogretmen B, et al. Biochemical mechanisms of the generation of endogenous long chain ceramide in response to exogenous short chain ceramide in the A549 human lung adenocarcinoma cell line. Role for endogenous ceramide in mediating the action of exogenous ceramide. J Biol Chem. 2002 Apr 12;277(15):12960-9. [Content Brief]

[2]. Macheleidt O, et al. Deficiency of epidermal protein-bound omega-hydroxyceramides in atopic dermatitis. J Invest Dermatol. 2002 Jul;119(1):166-73. [Content Brief]